Huons Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2016-05-03
- Employees
- 969
- Market Cap
- -
- Website
- http://www.huons.com
Clinical Trials
25
Active:1
Completed:16
Trial Phases
5 Phases
Phase 1:11
Phase 2:3
Phase 3:9
+2 more phases
Drug Approvals
2
FDA:2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Phase 1
11 (44.0%)Phase 3
9 (36.0%)Phase 2
3 (12.0%)Not Applicable
1 (4.0%)Phase 4
1 (4.0%)A Phase I Study to Evaluate the Safety and Drug Allergy of HLB3-002 in Healthy Volunteers
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Huonslab Co., Ltd.
- Target Recruit Count
- 243
- Registration Number
- NCT06713317
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B
Phase 1
Active, not recruiting
- Conditions
- Hypertension
- Interventions
- Drug: HUC2-565-A, HUC2-565-A and HUC2-565-BDrug: HUC2-565-B, HUC2-565-A and HUC2-565-B
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Huons Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06618079
- Locations
- 🇰🇷
Chungbuk national university hospital, Chungbuk, Korea, Republic of
Phase 1 Study in Diabetes Mellitus(Fasting)
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus
- Interventions
- Drug: HUC2-344-R1, HUC2-344-R2
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Huons Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06552182
- Locations
- 🇰🇷
Huons, Seoul, Korea, Republic of
Phase 1 Study in Diabetes Mellitus(Fed)
Phase 1
Completed
- Conditions
- Diabete MellitusDiabetes
- Interventions
- Drug: HUC2-344-R1, HUC2-344-R2
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Huons Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06551740
- Locations
- 🇰🇷
Huons, Seongnam-si, Gyeonggi-do, Korea, Republic of
To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome
Phase 3
Not yet recruiting
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: Hyalein Mini Drops
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Huons Co., Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT06388070
- Locations
- 🇰🇷
Gangbuk Samsung Hospital, Seoul, Jongno-gu, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found